Compare MFM & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFM | BNR |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.2M | 252.7M |
| IPO Year | N/A | 2019 |
| Metric | MFM | BNR |
|---|---|---|
| Price | $5.41 | $22.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 67.5K | 13.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $136.32 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $182.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.94 | $2.18 |
| 52 Week High | $5.67 | $41.72 |
| Indicator | MFM | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 35.68 | 40.29 |
| Support Level | $5.35 | $19.72 |
| Resistance Level | $5.47 | $24.23 |
| Average True Range (ATR) | 0.06 | 1.74 |
| MACD | -0.02 | -0.29 |
| Stochastic Oscillator | 0.04 | 27.09 |
MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but it may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.